Pfizer Inc. PFE

Key data

The business

Pfizer sells prescription medicines and vaccines worldwide. The filing splits the $15.0B it took in last quarter three ways: $11.9B from its own products, $2.7B from drugs it co-markets with partners, and $0.5B in royalties. The revenue engine is a short list of franchises, the Eliquis blood thinner shared with Bristol-Myers, the Prevnar pneumonia vaccines, the Vyndaqel heart drugs, a cancer portfolio bought with Seagen, and the COVID pair Comirnaty and Paxlovid, now a shrinking government-order line (about $2.0B of contracted orders remain, with $1.4B booked as prepaid deferred revenue). The pack does not break out revenue drug by drug.

The moat is the standard pharma one: patents granting years of monopoly pricing, wrapped in a global sales and regulatory machine few can match. The catch is that patents expire, and the filing says so without flinching, warning of "unfavorable impact from patent-based or regulatory exclusivity expiries over the next few years." That one sentence is the whole story. Pfizer is a portfolio of expiring monopolies racing to build new ones.

The numbers

Revenue is steady in the low-$60B range once the COVID spike washes out; the drama is all below the top line, where impairments and a steady $1.2B a quarter of intangible amortization swing the reported result from profit to loss.

Two of the last four quarters printed GAAP losses, yet the business underneath grew: Q2 revenue rose 2.6% over a year earlier and 4% over Q1, and adjusted earnings of $0.77 landed above the $0.68 the eight analysts modeled. The tell worth chewing on is the gap between that $0.77 and the four-cent GAAP loss. It is the write-down of the pipeline Pfizer paid up to build. If those charges keep coming, GAAP is the honest number and "adjusted" is the fiction.

Here is the compounding math, and it runs the wrong way. Street models see FY2028 revenue of $54.8B and FY2029 of $52.9B, with adjusted EPS slipping from about $2.49 to $2.36, modeling a managed decline as the patents roll off. So the trailing GAAP P/E of 37.6x is a trough optical, distorted by the loss quarters; on normalized GAAP earnings the stock is 19x, mid its twelve-year band of 14x to 23x, and on adjusted earnings nearer 9x with a forward FY2028 multiple around 11x. What I believe the tape underprices: the 2027-2028 cliff risk is real and the multiple at 19x assumes the pipeline fills the hole on time, when the filing warns plainly it might not. The 2027-2028 top line as Eliquis and other franchises face exclusivity expiry is the single print that decides whether 19x was cheap or a trap.

Management

The insiders are buying, and that is the loudest signal here. CEO Albert Bourla put about $1.0M of his own money in on August 12, and directors Blaylock and Buckley bought roughly $1.0M and $0.96M in early August, three open-market purchases against just $0.13M of sales (plan status not disclosed, but these are discretionary buys, not scheduled dribbles). Capital allocation is defensive and stated honestly: dividend first, buybacks paused until "after de-levering," and leverage expected to stay "around current levels, or modestly higher" through the transition. Cash fell to $976M from $1.7B a quarter earlier. The dividend-safety question that hung over this name a day ago has not cracked: net debt still sits near 4.9x EBITDA, unchanged, and the CEO added to his stake rather than trimmed it. Pay-for-performance detail is not in this pack.

How it fails or surprises you

The cliff bites harder than modeled. The filing warns of exclusivity expiries "over the next few years," and Eliquis is among the key franchises at risk. Street models already pencil revenue down through 2029; if generic erosion runs faster or a second franchise slips at once, the $54.8B FY2028 line proves optimistic and the multiple was a trap. Watch segment revenue through 2027.

Leverage forces a dividend choice (downside). Net debt is about 4.9x EBITDA, cash is down to $976M, and buybacks are frozen by the company's own words. If EBITDA falls with the cliff before the pipeline replaces it, the dividend and the credit rating start competing for the same cash. Watch operating cash flow, weak so far this year.

Obesity and oncology re-rate it (right tail). The Metsera obesity deal (about $600M of targeted synergies) plus the Seagen cancer drugs give Pfizer two shots at a new growth leg the market pays nothing for at 19x. If either obesity data or oncology scaling turns the modeled decline into flat-to-up, the whole earnings base and multiple reset. Watch Metsera clinical readouts and first obesity revenue.

Closing thoughts

The payoff here turns on prints you can watch over the next two years: segment revenue through the 2027-2028 exclusivity window and operating cash flow against the dividend. The patent losses are scheduled; whether the obesity and oncology pipeline replaces them is not, and that gap is the uncertainty. The distribution leans left in the near term because the exclusivity expiries are contractual while Metsera and Seagen are not, and leverage sits high enough that a revenue miss forces a dividend cut. What you risk if both hit is the dividend that is most of why anyone holds this. What you gain if the pipeline lands is a re-rating from shrinking to flat-or-up, which 19× pays nothing for.

The bet is still that Pfizer can replace the medicines about to lose their patents fast enough to keep its earnings from shrinking. It breaks if the top line falls faster than the pipeline fills it, and the one pair of numbers that tells you first is quarterly segment revenue against operating cash flow: when both turn down together, the read is wrong. The CEO is buying into that same gap with his own money.